Author's response to reviews

**Title:** Effect of delayed CNI-based immunosuppression with Advagraf(R) on liver function after MELD-based liver transplantation [IMUTECT]

**Authors:**

Susanne Richter (susannerichter@gmx.net)
Georg Polychronidis (Georg.Polychronidis@med.uni-heidelberg.de)
Daniel N Gotthardt (Daniel.Gotthardt@med.uni-heidelberg.de)
Philipp Houben (Philipp.Houben@med.uni-heidelberg.de)
Thomas Giese (giese@uni-hd.de)
Anja Sander (sander@imbi.uni-heidelberg.de)
Colette Doerr-Harim (Colette.Doerr-Harim@med.uni-heidelberg.de)
Markus K Diener (Markus.Diener@med.uni-heidelberg.de)
Peter Schemmer (Peter.Schemmer@med.uni-heidelberg.de)

**Version:** 4  
**Date:** 5 August 2014

**Author’s response to reviews:** see over
August 3rd, 2014

Dear Editors,

according to the reviewer's suggestions we have made the following amendments:

1. We have added the CMV prophylaxis scheme
2. We have emphasized, that Advagraf is a standard immunosuppression at our institution
3. We already look at clinically relevant measures of liver function (serum bilirubin, INR, serum transaminase peaks); episodes of rejection are documented and kidney function is well monitored (creatinine, glomerular filtration rate).

Thank you very much for your consideration.

Yours sincerely,

Susanne Richter